Attached files

file filename
EX-31.1 - EX-31.1 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-31_1.htm
EX-21.1 - EX-21.1 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-21_1.htm
EX-23.1 - EX-23.1 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-23_1.htm
EX-10.21 - EX-10.21 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-10_21.htm
EX-10.20 - EX-10.20 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-10_20.htm
EX-10.8(C) - EX-10.8(C) - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-10_8c.htm
EX-10.22 - EX-10.22 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-10_22.htm
EXCEL - IDEA: XBRL DOCUMENT - KYTHERA BIOPHARMACEUTICALS INCFinancial_Report.xls
10-K - 10-K - KYTHERA BIOPHARMACEUTICALS INCa2223273z10-k.htm
EX-31.2 - EX-31.2 - KYTHERA BIOPHARMACEUTICALS INCa2223273zex-31_2.htm

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the Annual Report of KYTHERA Biopharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission (the "Report"), Keith R. Leonard, Jr., President and Chief Executive Officer of the Company and John W. Smither, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 2, 2015

/s/ KEITH R. LEONARD, JR.

President and Chief Executive Officer
   

/s/ JOHN W. SMITHER

Chief Financial Officer

 

 



QuickLinks

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002